Xenotech in Forum 2/11/04 with Pfizer
Annual Forum on ADME/Tox
February 11 - 12, 2004 Philadelphia, PA Conference Summary
CONFERENCE SUMMARY SPEAKER FACULTY SPONSORS / EXHIBITORS MEDIA PARTNERS REGISTER
"I got a good primer on some of the new thoughts/ideas on safety assessment of drugs."
-- Shripad Bhagwat, Vice President, Drug Discovery, Celgene Signal Research Division
“Congregating researchers and executives with a range of backgrounds and experiences was a very unique benefit of this conference.”
-- Marty Pagel, Senior MRI Spectroscopy, Pharmacia
“A good summary of current methods for metabolism and toxicity prediction by those who use them.”
-- Boyd Steere, Senior Scientist, Simulations Plus
A new report from Frost & Sullivan "World ADME/Tox in Drug Development Markets" reports that revenues in the pharmaceutical industry totaled $1,043 million in 2002 and expect an increase to $2,204 million by 2009. The report highlights the need for improved data to facilitate superior research methods and expects to spur the demand for ADME/Tox in the drug development markets. The report also believes the fragmented nature of the currently available ADME/Tox technologies will move towards being replaced by an all-in-one solution, which in turn attracts heavy investments and better adoption rates.
For over four years CBI has gathered together the industry's leaders in metabolic and toxicological studies to provide attendees with a powerful opportunity to learn implementable strategies, scientific methods and to hear about the successes and failures of the latest technologies and models. CBI's 5th Annual Forum on ADME/Tox, February 11-12, 2004 is a comprehensive program that gives specific ADME/Tox strategies and enhances collaboration between scientists working in drug metabolism and drug toxicity.
Learn from the over 16 industry experts from Abbott Labs, Amgen, Aventis, Cephalon, Eli Lilly & Co., Millennium, National Center for Toxicological Research, National Institutes of Health, Novartis, Paradigm Genetics, Pfizer and Xenotech LLC on the new methods and tools you can use to predict drug metabolism and toxicity more quickly to minimize attrition rates.
2004 ADME/Tox Advisory Board:
Jeffrey Waring, Ph.D., Senior Research Scientist, Abbott Laboratories
Kin-Kai Hwang, Ph.D., Director/Senior Scientist, Aventis Pharmaceuticals
James M. Grace, Ph.D., Head, Lead Optimization, Metabolism and ADMET Screening Groups in Discovery Drug Disposition and New Technologies, Eli Lilly and Company
Rakesh Dixit, Ph.D., Senior Research Scientist, Merck & Co.
Sven Beushausen, Ph.D., Associate Director of the Proteomics Center of Expertise,
WorldWide Safety Sciences, Pfizer Inc
AI
